GFAP and early-onset autosomal dominant Alzheimer disease: Moreover, there is evidence that higher levels of CSF GFAP are associated with cognitive decline in Alzheimer’s disease patients at early stages of dementia [236] and also correlate with the severity of dementia [156] (Table 2).